Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. Imeglimin, a novel first-in-class small molecule tetrahydrotriazine drug candidate, improves glycemia and GSIS in preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894908/
https://www.ncbi.nlm.nih.gov/pubmed/33606677
http://dx.doi.org/10.1371/journal.pone.0241651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894908/
https://www.ncbi.nlm.nih.gov/pubmed/33606677
http://dx.doi.org/10.1371/journal.pone.0241651

Ejemplares similares